Resurgent Financial Advisors LLC decreased its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 3.5% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,493 shares of the company’s stock after selling 522 shares during the quarter. Johnson & Johnson comprises about 1.3% of Resurgent Financial Advisors LLC’s portfolio, making the stock its 10th biggest position. Resurgent Financial Advisors LLC’s holdings in Johnson & Johnson were worth $2,560,000 at the end of the most recent quarter.
A number of other institutional investors have also recently made changes to their positions in JNJ. Moneta Group Investment Advisors LLC boosted its position in shares of Johnson & Johnson by 90,144.4% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock worth $9,607,414,000 after purchasing an additional 54,326,454 shares in the last quarter. Norges Bank acquired a new stake in Johnson & Johnson during the 4th quarter worth about $4,609,399,000. Morgan Stanley lifted its position in Johnson & Johnson by 12.0% during the 4th quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock worth $7,458,962,000 after acquiring an additional 4,521,062 shares during the period. Nordwand Advisors LLC acquired a new stake in Johnson & Johnson during the 4th quarter worth about $785,273,000. Finally, Price T Rowe Associates Inc. MD lifted its position in Johnson & Johnson by 15.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 29,277,774 shares of the company’s stock worth $5,171,919,000 after acquiring an additional 3,849,148 shares during the period. Institutional investors and hedge funds own 67.94% of the company’s stock.
Wall Street Analysts Forecast Growth
JNJ has been the subject of a number of research reports. TheStreet cut Johnson & Johnson from a “b” rating to a “c+” rating in a research report on Friday, May 19th. Atlantic Securities lowered their price target on Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating for the company in a research report on Wednesday, April 19th. Morgan Stanley lifted their price target on Johnson & Johnson from $179.00 to $183.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 19th. UBS Group initiated coverage on Johnson & Johnson in a research note on Tuesday, March 28th. They set a “neutral” rating and a $164.00 price objective for the company. Finally, Citigroup initiated coverage on Johnson & Johnson in a research note on Tuesday, May 30th. They set a “buy” rating and a $185.00 price objective for the company. Seven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average target price of $171.57.
Insiders Place Their Bets
Johnson & Johnson Price Performance
Shares of Johnson & Johnson stock opened at $161.56 on Thursday. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.49. Johnson & Johnson has a twelve month low of $150.11 and a twelve month high of $183.35. The business has a 50-day moving average price of $160.77 and a 200 day moving average price of $164.16. The firm has a market cap of $419.85 billion, a PE ratio of 33.80, a P/E/G ratio of 2.73 and a beta of 0.54.
Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its quarterly earnings results on Tuesday, April 18th. The company reported $2.68 earnings per share for the quarter, beating the consensus estimate of $2.51 by $0.17. Johnson & Johnson had a return on equity of 36.13% and a net margin of 13.22%. The firm had revenue of $24.75 billion during the quarter, compared to analyst estimates of $23.61 billion. During the same quarter in the previous year, the business earned $2.67 EPS. Johnson & Johnson’s revenue for the quarter was up 5.6% compared to the same quarter last year. Sell-side analysts predict that Johnson & Johnson will post 10.66 earnings per share for the current fiscal year.
Johnson & Johnson Increases Dividend
The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 6th. Shareholders of record on Tuesday, May 23rd were paid a dividend of $1.19 per share. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.13. This represents a $4.76 annualized dividend and a yield of 2.95%. The ex-dividend date of this dividend was Monday, May 22nd. Johnson & Johnson’s payout ratio is 99.58%.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Read More
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- Game-Changing News For AMD And Its Shareholders
- How to Read Stock Charts for Beginners
- Can Chegg’s AI Pivot Save It From Disruption?
- Best Investment Strategy in 2023: Determine the Right One for You
- Enovix: A Rising Power in the Lithium-Ion Industry
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
